The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease: A placebo-controlled, randomized, open, cross-over study

Kidney and Blood Pressure Research

Volumn 31, Issue 6, 2009, Pages 404-410

  Renke, Marcin ^a   Tylicki, Leszek ^a   Rutkowski, Przemysław ^a   Larczyński, Wojciech ^a   Aleksandrowicz, Ewa ^a   Łysiak Szydłowska, Wiesława ^a   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Chronic kidney disease; N Acetylcysteine; Proteinuria; Tubular injury

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY FIBROSIS; KIDNEY FUNCTION; LABORATORY TEST; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TUBULAR DYSFUNCTION;

ACETYLCYSTEINE; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FIBROSIS; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES; MALE; PROTEINURIA; TREATMENT OUTCOME;

EID: 57649132131     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000185828     Document Type: Article

References (53)

1. Tylicki L, Larczynski W, Rutkowski B: Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives. Kidney Blood Press Res 2005;28:230-242.
2. Renke M, Tylicki L, Rutkowski P, Rutkowski B: Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. Scand J Urol Nephrol 2004;38:427-433.
3. Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B: Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients. Scand J Urol Nephrol 2005;39:511-517.
4. Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004;43:260-268.
5. Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B: Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007;7:243-248.
6. Tylicki L, Rutkowski P, Renke M, Rutkowski B: Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney Int 2007;72: 1164-1165.
7. Tylicki L, Rutkowski B, Horl WH: Antioxidants: a possible role in kidney protection. Kidney Blood Press Res 2003;26:303-314.
8. Aruoma O, Halliwell B, Hoey B, Butler J: The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989;6:593-597.
9. Modi M, Kaul RK, Kannan GM, Flora SJ: Coadministration of zinc and n-acetylcysteine prevents arsenic-induced tissue oxidative stress in male rats. J Trace Elem Med Biol 2006;20:197-204.
10. de Araujo M, Andrade L, Coimbra TM, Rodrigues AC Jr, Seguro AC: Magnesium supplementation combined with N-acetylcysteine protects against postischemic acute renal failure. J Am Soc Nephrol 2005;16:3339-3349.
11. Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, Carey RM, De Gasparo M, Cooper ME: Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002;13:1773-1787.
12. Yenicerioglu Y, Yilmaz O, Sarioglu S, Ormen M, Akan P, Celik A, Camsari T: Effects of N-acetylcysteine on radiocontrast nephropathy in rats. Scand J Urol Nephrol 2006;40:63-69.
13. Sahin G, Yalcin AU, Akcar N: Effect of N-acetylcysteine on endothelial dysfunction in dialysis patients. Blood Purif 2007;25:309-315.
14. Ristikankare A, Kuitunen T, Kuitunen A, Uotila L, Vento A, Suojaranta-Ylinen R, Salmenpera M, Poyhia R: Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth 2006;97:611-616.
15. Macedo E, Abdulkader R, Castro I, Sobrinho AC, Yu L, Vieira JM Jr: Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair - a randomized controlled trial. Nephrol Dial Transplant 2006;21:1863-1869.
16. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27:58-65.
17. Maruhn D: Rapid calorimetric assay of β-galactosidase and N-acetyl-β-D-glucosaminidase in human urine. Clin Chim Acta 1976;73:453-461.
18. Goligorsky M, Morgan M, Suh H, Safirstein R, Johnson R: Mild oxidative stress: cellular mode of mitogenic effect. Ren Fail 1992;14: 385-389.
19. Hannken T, Schroeder R, Stahl RA, Wolf G: Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 1998;54:1923-1933.
20. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z: Reactive oxygen species induce apoptosis in cultured human mesangial cells. J Am Soc Nephrol 1996;7:2357-2363.
21. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
22. Griendling K, Minieri C, Ollerenshaw J, Alexander R: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
23. Keaney JJ, Xu A, Cunningham D, Jackson T, Frei B, Vita J: Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest 1995;95: 2520-2529.
24. Iuliano L: The oxidant stress hypothesis of atherogenesis. Lipids 2001;36(suppl):S41-S44.
25. Nath K, Grande J, Croatt A, Haugen J, Kim Y, Rosenberg M: Redox regulation of renal DNA synthesis, transforming growth factor-beta1 and collagen gene expression. Kidney Int 1998;53:367-381.
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-869.
27. Moriyama T, Kawada N, Nagatoya K, Horio M, Imai E, Hori M: Oxidative stress in tubulointerstitial injury: therapeutic potential of antioxidants towards interstitial fibrosis. Nephrol Dial Transplant 2000;15:47-49.
28. Trolliet MR, Rudd MA, Loscalzo J: Oxidative stress and renal dysfunction in salt-sensitive hypertension. Kidney Blood Press Res 2001;24:116-123.
29. Young MR, Young IS, Johnston SR, Rowlands BJ: Lipid peroxidation assessment of free radical production following release of obstructive uropathy. J Urol 1996;156:1828-1832.
30. Wang J, Ger L, Tseng H: Expression of glomerular antioxidant enzymes in human glomerulonephritis. Nephron 1997;76:32-38.
31. Macconi D, Zanoli A, Orisio S, Longaretti L, Magrini L, Rota S, Radice A, Pozzi C, Remuzzi G: Methylprednisolone normalizes superoxide anion production by polymorphs from patients with ANCA-positive vasculitides. Kidney Int 1993;44:215-220.
32. Shan Z, Tan D, Satriano J, Silbiger S, Schlöndorff D: Intracellular glutathione influences collagen generation by mesangial cells. Kidney Int 1994;46:388-395.
33. Boesgaard S, Aldershvile J, Poulsen HE, Christensen S, Dige-Petersen H, Giese J: N-acetylcysteine inhibits angiotensin converting enzyme in vivo. J Pharmacol Exp Ther 1993;265:1239-1244.
34. Loske C, Neumann A, Cunningham A, Nichol K, Schinzel R, Riederer P, Munch G: Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm 1998;105:1005-1015.
35. Hultberg B, Andersson A, Masson P, Larson M, Tunek A: Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand J Clin Lab Invest 1994;54:417-422.
36. Tian N, Rose RA, Jordan S, Dwyer TM, Hughson MD, Manning RD Jr: N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension. J Hypertens 2006;24:2263-2270.
37. Otieno M, Anders M: Cysteine S-conjugates activate transcription factor NF-kappa B in cultured renal epithelial cells. Am J Physiol 1997;273:F136-F143.
38. Rangan GK, Wang Y, Tay YC, Harris DC: Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999;56:118-134.
39. Girardi G, Elias MM: Effectiveness of N-acetylcysteine in protecting against mercuric chloride-induced nephrotoxicity. Toxicology 1991;67:155-164.
40. Tariq M, Morais C, Sobki S, Al Sulaiman M, Al Khader A: N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol Dial Transplant 1999;14:923-929.
41. Pincemail J, Defraigne JO, Detry O, Franssen C, Meurisse M, Limet R: Ischemia-reperfusion injury of rabbit kidney: comparative effects of desferrioxamine and N-acetylcysteine as antioxidants. Transplant Proc 2000; 32:475-476.
42. Di Giorno C, Pinheiro HS, Heinke T, Franco MF, Galante NZ, Pacheco-Silva A, Camara NO: Beneficial effect of N-acetyl-cysteine on renal injury triggered by ischemia and reperfusion. Transplant Proc 2006;38:2774-2776.
43. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
44. Tepel M, Aspelin P, Lameire N: Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006;113:1799-1806.
45. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ: A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-2118.
46. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, Sutander A, Williams T, Fox RS, Levin A: A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004;148:422-429.
47. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, Seidelin P, Daly P, Ross J, McLaughlin PR, Ing D, Lewycky P, Barolet A, Schwartz L: N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 2004;148:690-695.
48. Bohle A, Mackensen-Haen S, von Gise H, Grund K, Wehrmann M, Batz C, Bogenschutz O, Schmitt H, Nagy J, Muller C, Muller G: The consequences of tubulo-interstitial changes for renal function in glomerulopathies. Pathol Res Pract 1990;186:135-144.
49. Teppo AM, Tornroth T, Honkanen E, Gronhagen-Riska C: Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation 2003; 75:2113-2119.
50. Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, D'Amico G: Urinary N-acetylglucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002;17:1890-1896.
51. Holdt-Lehmann B, Lehmann A, Korten G, Nagel H, Nizze H, Schuff-Werner P: Diagnostic value of urinary alanine aminopeptidase and N-acetyl-beta-D- glucosaminidase in comparison to alpha-1 microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin Chim Acta 2000;297:93-102.
52. Burgunder J, Varriale A, Lauterburg B: Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989;36:127-131.
53. Kleinveld H, Demacker P, Stalenhoef A: Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects. Eur J Clin Pharmacol 1992;43:639-642.